DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
Frankel AE, Fleming DR, Powell BL, Gartenhaus R.
Frankel AE, et al.
Expert Opin Biol Ther. 2003 Feb;3(1):179-86. doi: 10.1517/14712598.3.1.179.
Expert Opin Biol Ther. 2003.
PMID: 12718740
Review.
Based on the presence of high affinity interleukin-2 receptor (IL-2R) on CLL cells, therapy of relapsed CLL patients with a diphtheria fusion protein targeting IL-2R - DAB(389)IL2 (ONTAK), Seragen, Inc., Hopkinton, MA, USA) - was tested in a pilot Phase II study. ...
Based on the presence of high affinity interleukin-2 receptor (IL-2R) on CLL cells, therapy of relapsed CLL patients with a diphtheria fusio …